{"id":"ypeginterferon-alfa-2b","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Flu-like symptoms"},{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Headache"},{"rate":"20-40%","effect":"Myalgia"},{"rate":"10-30%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201561","moleculeType":"Protein"},"_fixedAt":"2026-03-30T11:49:31.571182","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by enhancing the body's natural immune response to fight viral infections and cancer cells. Interferons are proteins that are naturally produced by the body to fight off viral infections, and Ypeginterferon alfa-2b is a synthetic version of one of these proteins. By stimulating the immune system, it can help to reduce the severity of symptoms and slow down the progression of diseases.","oneSentence":"Ypeginterferon alfa-2b is a recombinant form of interferon alfa-2b used to modulate the immune system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:14.383Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of chronic hepatitis B"},{"name":"Treatment of chronic hepatitis C"}]},"_fixedFields":["pubmed(1460)"],"trialDetails":[{"nctId":"NCT02332473","phase":"PHASE2","title":"A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2014-06","conditions":"Chronic Hepatitis B","enrollment":110},{"nctId":"NCT01760122","phase":"PHASE3","title":"Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2013-03","conditions":"Chronic Hepatitis B","enrollment":820},{"nctId":"NCT01581398","phase":"PHASE3","title":"Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2012-04","conditions":"Chronic Hepatitis C","enrollment":770},{"nctId":"NCT01143662","phase":"PHASE2","title":"Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2010-07","conditions":"Chronic Hepatitis B","enrollment":205},{"nctId":"NCT01140997","phase":"PHASE2","title":"Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2010-07","conditions":"Chronic Hepatitis C","enrollment":211}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1460,"recentPublications":[{"date":"2026","pmid":"41905910","title":"[Hematologic responses with favorable safety in three elderly patients with polycythemia vera treated with ropeginterferon alfa-2b].","journal":"[Rinsho ketsueki] The Japanese journal of clinical hematology"},{"date":"2026","pmid":"41905909","title":"[Sustained molecular response after discontinuation of ropeginterferon alfa-2b in a young patient with polycythemia vera].","journal":"[Rinsho ketsueki] The Japanese journal of clinical hematology"},{"date":"2026","pmid":"41905908","title":"[Sustained hematologic complete response after discontinuation of ropeginterferon alfa-2b in patients with polycythemia vera].","journal":"[Rinsho ketsueki] The Japanese journal of clinical hematology"},{"date":"2026 Mar 28","pmid":"41902804","title":"Polycythemia vera.","journal":"Mayo Clinic proceedings"},{"date":"2026 Mar 23","pmid":"41875300","title":"Host-viral interaction of HBV infection revealed by single-cell transcriptome jointly profiling the viral replication state.","journal":"Hepatology (Baltimore, Md.)"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Peginterferon alfa-2b","peginterferon alfa-2b"],"phase":"phase_3","status":"active","brandName":"Ypeginterferon alfa-2b","genericName":"Ypeginterferon alfa-2b","companyName":"Xiamen Amoytop Biotech Co., Ltd.","companyId":"xiamen-amoytop-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ypeginterferon alfa-2b is a recombinant form of interferon alfa-2b used to modulate the immune system. Used for Treatment of chronic hepatitis B, Treatment of chronic hepatitis C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}